IC
CGON icon

Ikarian Capital’s CG Oncology CGON Stock Holding History

Ikarian Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-199,473
Closed -$8.28M – 175
2025
Q4 		$8.28M Sell
199,473
-50,000
-20% -$2.07M 0.65% 43
2025
Q3 		$10M Buy
249,473
+94,473
+61% +$2.75M 1.01% 27
2025
Q2 		$4.03M Buy
+155,000
New +$3.74M 0.77% 40

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital's CGON Position: Q1 2026 in Review

Ikarian Capital sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 199,473 shares — an estimated $8.28M sold.

Ikarian Capital first reported a position in CGON in Q2 2025 and held it in 3 quarters. The position peaked at $10M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Ikarian Capital reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 199,473 CG Oncology shares in Q1 2026, an estimated $8.28M.
  • Ikarian Capital first reported a position in CG Oncology in Q2 2025 and held it in 3 quarters.
  • Ikarian Capital's CG Oncology position peaked at $10M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.